140 related articles for article (PubMed ID: 38547721)
1. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Nagaraj H; Williams M; Wang H; Lee A; Sun E; Teo EL; Tan E; Goh KC; Dymock B
J Mol Model; 2013 Jan; 19(1):119-30. PubMed ID: 22820730
[TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
Niu P; Tao Y; Meng Q; Huang Y; Li S; Ding K; Ma D; Ye Z; Fan M
Bioorg Med Chem; 2024 Apr; 104():117711. PubMed ID: 38583237
[TBL] [Abstract][Full Text] [Related]
5. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
6. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
7. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
8. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
11. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
Shaikh J; Patel K; Khan T
Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
[TBL] [Abstract][Full Text] [Related]
13. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
15. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Lin T; Li J; Liu L; Li Y; Jiang H; Chen K; Xu P; Luo C; Zhou B
Eur J Med Chem; 2021 Apr; 215():113281. PubMed ID: 33611192
[TBL] [Abstract][Full Text] [Related]
17. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
[TBL] [Abstract][Full Text] [Related]
19. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
20. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
